All these insights could help to inform the development of targeted therapeutic strategies for diseases associated with chromatin dysfunction, such as inflammatory conditions and cancers, by manipulating the pathways that regulate H3.3 phosphorylation and FACT function. Here, SUPT16H is linked to cancer.